The state of Illinois currently has 7 active clinical trials seeking participants for Diabetic Macular Edema research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
Recruiting
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: University Retina and Macula Associates, Oak Forest, Illinois
Conditions: Diabetic Macular Edema
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Recruiting
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: University Retina and Macula Associates, PC, Oak Forest, Illinois
Conditions: Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Recruiting
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products (Faricimab and Port Delivery System with Ranibizumab) in approved retinal indications (neovascular age-related macular degeneration... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: University Retina and Macula Associates, PC, Oak Forest, Illinois +1 locations
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Evaluation of Tonabersat for DME
Recruiting
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Illinois Retina Associates, Oak Park, Illinois
Conditions: Diabetic Macular Edema
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Recruiting
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding pa... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
12/05/2023
Locations: Lemont, NV, Lemont, Illinois
Conditions: Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
Recruiting
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: Assess the efficacy of foselutoclax compared to aflibercept Assess the safety and tolerability of foselutoclax
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: University Retina and Macula Associates, Lemont, Illinois
Conditions: Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)
Recruiting
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: University Retina - Lemont, Lemont, Illinois
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema